Myelodysplastic Syndromes (MDS) and Deferasirox

Use of deferasirox in transfusional iron overload from lower-risk myelodysplastic syndromes (MDS) - patient selection, dosing, tolerability and monitoring.

Lower-risk myelodysplastic syndromes (MDS) often require regular red-cell transfusion, leading to transfusional iron overload. In selected lower-risk patients with prolonged transfusion need, deferasirox provides oral once-daily iron chelation - while requiring careful patient selection and monitoring given the underlying hematological disease.

Disease Background #

Myelodysplastic syndromes are clonal stem-cell disorders characterised by ineffective haematopoiesis, peripheral cytopenias and a variable risk of progression to acute myeloid leukemia. The IPSS / IPSS-R risk classification stratifies patients - lower-risk MDS (IPSS Low/Int-1; IPSS-R Very Low / Low / Intermediate) is the population most likely to receive prolonged transfusion support.

Why Iron Chelation Matters in MDS #

  • Lower-risk MDS patients may live many years on transfusion support and accumulate clinically significant iron loads.
  • Iron overload may worsen cytopenias and contribute to organ dysfunction.
  • Some retrospective evidence suggests chelation is associated with improved survival in selected lower-risk patients - although prospective evidence is limited and patient selection matters.
  • Patients being considered for allogeneic stem-cell transplant with high pre-transplant iron loads may benefit from chelation given iron loading's impact on transplant outcomes.

Patient Selection Criteria (typical) #

  • Lower-risk MDS by IPSS / IPSS-R
  • Transfusion-dependent (typically >= 20-30 units cumulative or serum ferritin persistently > 1000-2500 ng/mL)
  • Expected survival sufficient to benefit from chelation (often >= 1-2 years)
  • Adequate renal and hepatic function for therapy

Tolerability & Monitoring in MDS #

MDS patients are typically older with comorbidities and baseline cytopenias - so monitoring is more intensive than in younger thalassemia patients:

  • CBC weekly during initiation; cytopenia worsening warrants reassessment.
  • Renal function (creatinine, CrCl) and liver enzymes monthly.
  • Serum ferritin monthly; trend matters more than single values given inflammation.
  • Caution with concomitant nephrotoxins.
  • Discontinue immediately on signs of SCAR (SJS / TEN / DRESS), GI hemorrhage or hepatic / renal failure.

Practical Dosing #

Starting doses in MDS are typically lower than in thalassemia (e.g. around 10-20 mg/kg/day with the dispersible formulation), titrated by ferritin trend and tolerability. Refer to the locally approved prescribing information for definitive dosing.

DEFRATAJ in MDS Programmes #

DEFRATAJ is supplied in five strengths (100/125/250/400/500 mg dispersible tablets) - the 100 mg and 125 mg unit sizes are particularly useful for the careful titration required in MDS. See DEFRATAJ 100 mg and DEFRATAJ 125 mg for product details.